This double-blind, placebo-controlled RCT tested whether a 90-day course of amoxicillin-clavulanate reduces pain in chronic low back pain with disc herniation. It recruited community-dwelling adults aged 18 to 60 with an MRI-confirmed disc herniation. The key question: does treating a possible low-grade disc infection improve pain at 12 months, including in patients with Modic changes?
Do not prescribe antibiotics for chronic low back pain with disc herniation, even when the MRI shows Modic changes and other treatments have failed.
The disc-infection hypothesis is appealing: low-virulence organisms like Cutibacterium acnes have been cultured from herniated discs, and type 1 Modic changes were thought to mark that infection. An earlier trial by Albert selected for Modic type 1 and reported benefit, which drove real prescribing.
This trial used a broad-spectrum agent, enrolled a wider real-world population, and found nothing, including in the Modic subgroup. Because coverage was broad, the null result cannot be dismissed as too narrow an antibiotic. Remember the balance of harm: the antibiotic group had more adverse events and more dropouts from them, plus the population-level cost of antimicrobial resistance.
When a patient asks about antibiotics for their back pain from something they read online, this is the trial to cite.
This double-blind, placebo-controlled RCT tested whether a 90-day course of amoxicillin-clavulanate reduces pain in chronic low back pain with disc herniation. It recruited community-dwelling adults aged 18 to 60 with an MRI-confirmed disc herniation. The key question: does treating a possible low-grade disc infection improve pain at 12 months, including in patients with Modic changes?
Do not prescribe antibiotics for chronic low back pain with disc herniation, even when the MRI shows Modic changes and other treatments have failed.
The disc-infection hypothesis is appealing: low-virulence organisms like Cutibacterium acnes have been cultured from herniated discs, and type 1 Modic changes were thought to mark that infection. An earlier trial by Albert selected for Modic type 1 and reported benefit, which drove real prescribing.
This trial used a broad-spectrum agent, enrolled a wider real-world population, and found nothing, including in the Modic subgroup. Because coverage was broad, the null result cannot be dismissed as too narrow an antibiotic. Remember the balance of harm: the antibiotic group had more adverse events and more dropouts from them, plus the population-level cost of antimicrobial resistance.
When a patient asks about antibiotics for their back pain from something they read online, this is the trial to cite.